These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thinking while balancing: what to do about replacing dropouts. Shader RI; Harmatz JS; Greenblatt DJ J Clin Psychopharmacol; 1994 Aug; 14(4):229. PubMed ID: 7962677 [No Abstract] [Full Text] [Related]
5. Analysis of longitudinal binary data with missing data due to dropouts. Ali MW; Talukder E J Biopharm Stat; 2005; 15(6):993-1007. PubMed ID: 16279357 [TBL] [Abstract][Full Text] [Related]
6. Reading reports of clinical trial results. Kane JM J Clin Psychiatry; 2005 May; 66(5):653. PubMed ID: 15889955 [No Abstract] [Full Text] [Related]
7. Effect of dropouts on sample size estimates for test on trends across repeated measurements. Ahn C; Jung SH J Biopharm Stat; 2005; 15(1):33-41. PubMed ID: 15702603 [TBL] [Abstract][Full Text] [Related]
8. Statistical handling of drop-outs in longitudinal clinical trials. Harris RI Stat Med; 1993 Dec; 12(23):2248-50. PubMed ID: 8310194 [No Abstract] [Full Text] [Related]
9. Stereotyping and the treatment of missing data for drug and alcohol clinical trials. Arndt S Subst Abuse Treat Prev Policy; 2009 Feb; 4():2. PubMed ID: 19226454 [TBL] [Abstract][Full Text] [Related]
10. A bias correction in testing treatment efficacy under informative dropout in clinical trials. Kong F; Chen YF; Jin K J Biopharm Stat; 2009 Nov; 19(6):980-1000. PubMed ID: 20183460 [TBL] [Abstract][Full Text] [Related]
12. Testing for treatment differences with dropouts present in clinical trials--a composite approach. Shih WJ; Quan H Stat Med; 1997 Jun; 16(11):1225-39. PubMed ID: 9194269 [TBL] [Abstract][Full Text] [Related]
13. Addressing missing data in clinical trials. van der Laan M; Lorenz TJ Ann Intern Med; 2011 Jul; 155(2):135. PubMed ID: 21768593 [No Abstract] [Full Text] [Related]
14. Bayesian analysis of hierarchical pattern-mixture models for clinical trials data with attrition and comparisons to commonly used ad-hoc and model-based approaches. Demirtas H J Biopharm Stat; 2005; 15(3):383-402. PubMed ID: 15920887 [TBL] [Abstract][Full Text] [Related]
16. Adjusting for drop-out in clinical trials with repeated measures: design and analysis issues. Wu MC; Albert PS; Wu BU Stat Med; 2001 Jan; 20(1):93-108. PubMed ID: 11135350 [TBL] [Abstract][Full Text] [Related]
17. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information. Goyal N; Gomeni R Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266 [TBL] [Abstract][Full Text] [Related]
18. A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials. Goyal N; Gomeni R Eur Neuropsychopharmacol; 2013 Nov; 23(11):1570-6. PubMed ID: 23602612 [TBL] [Abstract][Full Text] [Related]
19. Ignorability and bias in clinical trials. Heitjan DF Stat Med; 1999 Sep 15-30; 18(17-18):2421-34. PubMed ID: 10474150 [TBL] [Abstract][Full Text] [Related]
20. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets. Siddiqui O J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]